Department of Toxicology, University of Cagliari, Cagliari, Italy.
Neuropharmacology. 2011 Mar;60(4):602-8. doi: 10.1016/j.neuropharm.2010.12.006. Epub 2010 Dec 23.
The function of 5-HT6 receptors, one of the last additions to the large family of 5-HT receptors, is largely unknown due to the limited knowledge of their transduction mechanisms, lack of full centrally acting agonists and inconsistencies in the pharmacological and neurochemical effects of the antagonists. Recently, a new full agonist, ST1936, with nanomolar affinity for 5-HT6 receptors, has become available. Here we report the effect of ST1936 (5-10-20 mg/kg/ip) on dialysate DA, NA and 5-HT in the medial prefrontal cortex (PFCX) and in the shell and core of the nucleus accumbens (NAc). Systemic administration of ST1936 dose-dependently increased dialysate DA and NA in the NAc shell and PFCX and to a lesser extent in the NAc core; these effects were prevented by systemic administration of the two 5-HT6 receptor antagonists, SB271046 (10-20 mg/kg/ip) and SB399885 (5 mg/kg/ip). These properties of ST1936 suggest that 5-HT6 receptors control the activity of DA and NA neurons projecting to the NAc and to the PFCX.
5-HT6 受体是 5-HT 受体大家族中的最新成员之一,其功能很大程度上是未知的,这是由于对其转导机制的了解有限,缺乏完全作用于中枢的激动剂,以及拮抗剂的药理学和神经化学作用存在不一致性。最近,一种新的全激动剂 ST1936 具有对 5-HT6 受体的纳摩尔亲和力。在这里,我们报告 ST1936(5-10-20mg/kg/ip)对伏隔核(NAc)壳和核心以及前额皮质(PFCX)中透析液 DA、NA 和 5-HT 的影响。ST1936 的全身给药剂量依赖性地增加了 NAc 壳和 PFCX 中透析液 DA 和 NA 的含量,在 NAc 核心中则较少;这些作用被两种 5-HT6 受体拮抗剂 SB271046(10-20mg/kg/ip)和 SB399885(5mg/kg/ip)的全身给药所阻止。ST1936 的这些特性表明 5-HT6 受体控制着投射到 NAc 和 PFCX 的 DA 和 NA 神经元的活性。